about
Treating patients with ventricular ectopic beatsDriving and arrhythmia: a review of scientific basis for international guidelinesnMARQ Ablation for Atrial Fibrillation: Results from a Multicenter Study.Arrhythmia detection by patient and auto-activation in implantable loop recorders.Safety and efficacy of multipolar pulmonary vein ablation catheter vs. irrigated radiofrequency ablation for paroxysmal atrial fibrillation: a randomized multicentre trial.Comparison of the performance of three diagnostic algorithms for regular broad complex tachycardia in practical application.Autonomic nerve stimulation reverses ventricular repolarization sequence in rabbit heartsThe reliable electrocardiographic diagnosis of regular broad complex tachycardia: a holy grail that will forever elude the clinician's grasp?The acute inotropic effects of cardiac contractility modulation (CCM) are associated with action potential duration shortening and mediated by β1-adrenoceptor signalling.hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes.hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.A novel surface electrocardiogram-based marker of ventricular arrhythmia risk in patients with ischemic cardiomyopathyEuropean survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation.Three-dimensional dominant frequency mapping using autoregressive spectral analysis of atrial electrograms of patients in persistent atrial fibrillationThe mechanical uncoupler blebbistatin is associated with significant electrophysiological effects in the isolated rabbit heart.Minimizing discordances in automated classification of fractionated electrograms in human persistent atrial fibrillation.Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension.Cardiac contractility modulation increases action potential duration dispersion and decreases ventricular fibrillation threshold via β1-adrenoceptor activation in the crystalloid perfused normal rabbit heart.Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions.Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation--tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failureVagal modulation of cardiac ventricular arrhythmia.Neuro-cardiac interaction in malignant ventricular arrhythmia and sudden cardiac death.Feasibility of selection of antiarrhythmic drug treatment on the basis of arrhythmogenic mechanism - Relevance of electrical restitution, wavebreak and rotors.Atrial Electrogram Fractionation Distribution before and after Pulmonary Vein Isolation in Human Persistent Atrial Fibrillation-A Retrospective Multivariate Statistical Analysis.Looks like VT But Isn't--successful ablation of a left free wall accessory pathway with Mahaim-like properties.PKC-mediated toxicity of elevated glucose concentration on cardiomyocyte function.Ganglionic plexus ablation during pulmonary vein isolation--predisposing to ventricular arrhythmias?Increase in organization index predicts atrial fibrillation termination with flecainide post-ablation: spectral analysis of intracardiac electrograms.Vagus nerve stimulation inhibits the increase in Ca2+ transient and left ventricular force caused by sympathetic nerve stimulation but has no direct effects alone--epicardial Ca2+ fluorescence studies using fura-2 AM in the isolated innervated beatiVagus nerve stimulation protects against ventricular fibrillation independent of muscarinic receptor activation.Effects of direct sympathetic and vagus nerve stimulation on the physiology of the whole heart--a novel model of isolated Langendorff perfused rabbit heart with intact dual autonomic innervation.Nitric oxide and cardiac parasympathetic control in human heart failure.Rationale and study design of the REM-HF study: remote management of heart failure using implanted devices and formalized follow-up procedures.The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.Direct evidence of nitric oxide release from neuronal nitric oxide synthase activation in the left ventricle as a result of cervical vagus nerve stimulation.Sympathetic nerve stimulation produces spatial heterogeneities of action potential restitution.A novel method of measuring nitric-oxide-dependent fluorescence using 4,5-diaminofluorescein (DAF-2) in the isolated Langendorff-perfused rabbit heart.Re: The atrioventricular delay of cardiac resynchronization can be optimized hemodynamically during exercise and predicted from resting measurements.Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial.The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias.
P50
Q24675999-8E49E2F6-F611-4ACE-AD5A-17C9FAD9F905Q27025928-B7712E12-556B-46B9-A0CE-1D3C498473FFQ30566686-BB876607-9730-4D21-A0FE-4C244CFF901EQ33151167-48AE710E-0D98-48E5-8687-ADDA447E6238Q33966136-ED1645AC-7D63-4E43-8C69-9BD89520FB82Q34131777-E4983E6B-4557-4558-AC4A-52CF4FACD4AEQ34493218-D9B31E8D-323D-4264-98AA-DA523A386BBFQ35042374-581E9C41-3D77-412E-81A2-B762CC4850EBQ35223644-3A36B7D7-7152-4F3F-9C91-80B3A1041FA1Q35932644-05C1C9DC-CAE9-4CCD-83BC-90D286AB5661Q36085808-0A1C8863-5031-48CF-ACE9-E1DBC8353A38Q36366302-EE6EF67E-2D99-492C-A956-7A1250160C4FQ36408743-206C73C1-2F46-407B-85D1-70726BA7A3DFQ36662966-EF0E6257-B5F9-4DA7-8F48-A6B76737DA18Q37073023-6A0ABD82-9537-47E6-AE18-55FE9F273CB9Q37348493-CB0AD147-2BD0-4D78-98B2-CBAC0BA690B1Q37556484-BF341227-990D-445E-91CB-15A76629E5A1Q37690133-626368D2-6175-4CAB-8B94-633EE9AFBC84Q37867850-E1678757-7A7E-404D-A0D1-AF428D49A171Q38017144-75DB4ED9-FF92-4FC8-AB40-F7CC09117783Q38135402-60C12896-D438-47A2-9D7E-88A166B60EA0Q38898758-3BDE7C87-7326-4128-95E0-6AD4B42B3247Q38981196-4C4C3162-3F54-4776-B693-B0A7319D3D5FQ41538861-613410FB-2D9C-4972-8E3D-4CC0ABBD106DQ41984336-0939F672-7110-434A-9A55-3C529703E118Q42461046-3548CED7-7BD9-4E95-92B6-36B781EEA8B8Q42931010-317F4118-C099-49F4-A8B0-39D797312243Q43214604-BACCA1D9-DEB4-457C-B798-E3685E9D7E58Q43287621-17192773-943E-4B40-9CD0-8B70CB3B1C58Q43627201-F253DC27-0F01-4A06-AB19-683668EC53D6Q43686622-E3162203-5DFB-4719-B3B8-AE6FBB46C782Q43932887-66B667CF-867B-49CD-8BAF-4DDE2CB8F641Q44621138-1272763B-6D84-4EDC-96D8-116F18F6865FQ44917641-C66F3E42-46B0-4456-A72E-9F13DA7FA050Q46031589-A0B400D5-C251-418E-A82C-A328A6A3821DQ46038921-8B1BF8E0-83E3-4408-9151-3A6887594CF8Q46818551-6577E106-D036-4532-A20C-6654D50ED509Q47313218-CA9E57E7-ACD3-4BDB-A16B-59A354FAA773Q47418812-CAA77A2E-E7A0-4B70-A491-B7B8DF2F9575Q47633903-48A72229-92FC-4D74-8895-B43EEF312577
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
G. Andre Ng
@ast
G. Andre Ng
@en
G. Andre Ng
@es
G. Andre Ng
@nl
G. Andre Ng
@sl
type
label
G. Andre Ng
@ast
G. Andre Ng
@en
G. Andre Ng
@es
G. Andre Ng
@nl
G. Andre Ng
@sl
prefLabel
G. Andre Ng
@ast
G. Andre Ng
@en
G. Andre Ng
@es
G. Andre Ng
@nl
G. Andre Ng
@sl
P106
P1153
7102563774
P2456
P2798
P31
P3835
g-andre-ng
P496
0000-0001-5965-0671